+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Painful Diabetic Neuropathy Drugs Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2021 to 2029

  • ID: 5353565
  • Report
  • May 2021
  • Region: Global
  • 105 pages
  • Acute Market Reports

FEATURED COMPANIES

  • Acorda Therapeutics
  • Collegium Pharmaceutical
  • Daiichi Sankyo Company
  • Eli Lilly and Company
  • Grunenthal GmbH
  • Lupin Pharmaceuticals.
  • MORE
The Painful Diabetic Neuropathy Drugs Market is forecasted to grow at a CAGR of 7% during the forecast period of 2019 to 2029. Painful diabetic peripheral neuropathy occurs in approximately 25% of patients with diabetes mellitus who have treated in the office sitting&sedentary lifestyle. It typically causes burning pain, paresthesias& numbness in a stocking-glove pattern that progress from the feet & hands. Healthcare should carefully consider the patient's goal, functional status & potential adverse effects of medication when choosing a treatment for painful diabetic peripheral neuropathy. Pregabalin and duloxetine are the two types of medications approved by the U.S. Food and Drug Administration for treating this disorder.


Peripheral Treatment trends the market

The treatment includes several medications such as, Anticonvulsants, Tricyclic antidepressants, Serotonin-norepinephrine reuptake inhibitors, Opioid-like medications, Topical medications, Selective serotonin reuptake inhibitors&Opioids. The medicines inhaled in this treatment costs about a range of 8$ - 560$. They also have adverse effect as, nausea, headache, dizziness, peripheral edema, weight gain, constipation, Diarrhea, anxiety, vomiting,Somnolence, insomnia & so on. The range of patients causing adverse effect may vary from 5 % to 60 %. Various treatments for Painful Diabetic Neuropathy but the most effective & efficient is the peripheral treatment.

Increasing Prevalence Remains the Key Impeder

Diabetes has become one of the largest global health care diseases of the 21 st century. According to the Centers for Disease Control and Prevention CDCP, the population prevalence of diabetes in the North America is approaching 10% and is increasing by 5% each year.The number of people with diabetes rose from 108 million in 1980 to 422 million in 2014. Spread of diabetes has been emerging more rapidly in low & middle income countries than in high income countries. Approximately, 60 million people in the European Region are living with this disease, by straining the Region’s economies and health systems.Prevalence of diabetes is increasing in the European Region hasreached 10-12% of the population in some of the States. This increase is strongly associated with increasing trends towards overweight and obesity, unhealthy diets, physical inactivity and socioeconomic disadvantage. This trend is significantly increasing the prevalence of diabetic Neuropathy as well.

Market

Key Players

Some of the key players include Daiichi Sankyo Company, Eli Lilly and Company, Johnson & Johnson Services, Novartis AG, Pfizer Inc, Grunenthal GmbH, ViroMed Co, Collegium Pharmaceutical, Acorda Therapeutics, Zydus Pharmaceuticals, Mallinckrodt, Macleods Pharmaceuticals Ltd, Lupin Pharmaceuticals.

Historical & Forecast Period

This research report presents the analysis of each segment from 2019 to 2029 considering 2020 as the base year for the research. Compounded annual growth rate (CAGR) for each respective segment are calculated for the forecast period from 2021 to 2029.

Report Scope by Segments

Market revenues and CAGR were derived from primary and secondary research. Both quantitative and qualitative trends were considered for extrapolation of market revenues. The derived market estimates were further validated from top down, bottom strategies and primary research. The scope of the market is limited to the following segments of product categories and region.

ATTRIBUTE DETAILS
  • Research Period 2019-2029
  • Base Year 2020
  • Forecast Period 2021-2029
  • Historical Year 2019
  • Unit US$ Million
Segmentation Drug Segment (2019-2029; US$ Mn)
  • Anticonvulsants
  • Tricyclic antidepressants
  • Serotonin-norepinephrine reuptake inhibitors
  • Opioid
  • Topical medications
  • Selective serotonin reuptake inhibitors
Disease Segment ( 2019-2029; US$ Mn)
  • Peripheral
  • Focal
  • Proximal
  • Autonomic
Application area Segment ( 2019-2029; US$ Mn)
  • Online Pharmaceuticals
  • Retail Pharmacy stores
  • Hospitals
Region type Segment (2019-2029; US$ Mn)
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Africa
Global Impact of Covid-19 Segment (2020-2021; US$ Mn )
  • Pre Covid-19 situation
  • Post Covid-19 situation
Key questions answered in this report
  • What are the key market segments in current scenario and in the future by product categories?
  • What are the key market segments in current scenario and in the future by regions?
  • What is the key impact of Covid-19 over market revenues and market determinants in the Painful Diabetic Neuropathy Drugs market?
  • What are the primary and secondary macro and micro factors influencing the market growth currently and during the forecast period?
  • What are the primary and secondary macro and micro factors deterring the market growth currently and during the forecast period?
  • How to overcome the current market challenges and leverage the opportunities in each of the market segment?
  • Who are the key players in the Painful Diabetic Neuropathy Drugs market and what are their key product categories and strategies?
  • What are the key strategies – mergers/acquisitions/R&D/strategic partnerships etc that companies are deploying to enhance market revenues and growth?
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Acorda Therapeutics
  • Collegium Pharmaceutical
  • Daiichi Sankyo Company
  • Eli Lilly and Company
  • Grunenthal GmbH
  • Lupin Pharmaceuticals.
  • MORE
Chapter1. Preface
1.1. Report Scope and Description
1.1.1. Study Purpose
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I-Secondary Research
1.3.2. Phase II-Primary Research
1.3.3. Phase III-Expert Panel Review
1.3.4. Approach Adopted
1.3.4.1. Top-Down Approach
1.3.4.2. Bottom-Up Approach
1.3.5. Assumptions
1.3.6. Market Segmentation

Chapter 2. Executive Summary
2.1. Global PDND Market Portraiture
2.2. Global PDND Market 2020 (US$ Mn)
2.3. Global PDND Market, by Region, 2020 (Value)
2.4 Global PDND Market, by Impact of Covid 19,2020 (US$ Mn)

Chapter 3. Painful Diabetic Neuropathy Drugs Market: Market Dynamics and Future Outlook
3.1. Market Overview
3.2. Current Scenario: New Product Launches
3.3. Drivers
3.4. Challenges
3.5. Opportunities
3.6. Attractive Investment Proposition, by Geography, 2020
3.7. Competitive Landscape
3.7.1. Competitive Landscape, by Key Players, 2020

Chapter 4. Painful Diabetic Neuropathy Market, by Drug Type, 2019 – 2029 (US$ Mn)
4.1. Overview
4.2. Anticonvulsants
4.3 Tricyclic antidepressants
4.4 Serotonin-norepinephrine reuptake inhibitors
4.5 Opioid
4.6 Topical medications
4.7 Selective serotonin reuptake inhibitors

Chapter 5. Painful Diabetic Neuropathy Drugs Market, by Disease Type, 2019 – 2029 (US$ Mn)
5.1. Overview
5.2. Peripheral
5.3 Focal
5.4 Proximal
5.5 Autonomic

Chapter 6. Painful Diabetic Neuropathy Drugs Market, by Application area, 2019 – 2029 (US$ Mn)
6.1. Overview
6.2. Online Pharmaceuticals
6.3 Retail Pharmacy stores
6.4 Hospitals

Chapter 7. Painful Diabetic Neuropathy Drugs Market, by Region, 2019 – 2029 (US$ Mn)
7.1. Overview
7.2. North America PDND Market Analysis, 2019 – 2029
7.2.1. North America PDND Market, by Drug Type, 2019 – 2029 (US$ Mn)
7.2.2. North AmericaPDND Market, by Disease Type, 2019 – 2029 (US$ Mn)
7.2.3. North America PDND Market, by Application, 2019 – 2029 (US$ Mn)
7.2.4. North America PDND Market, by Country, 2019 – 2029 (US$ Mn)
7.2.4.1. U.S.
7.2.4.2. Canada

Chapter 8. Europe PDND Market Analysis, 2019 – 2029
8.1. Europe PDND Market, by Drug Type, 2019 – 2029 (US$ Mn)
8.2. Europe PDND Market, by Disease Type, 2019 – 2029 (US$ Mn)
8.3. Europe PDND Market, by Application area, 2019 – 2029 (US$ Mn)
8.4. Europe PDND Market, by Country/Region, 2019 – 2029 (US$ Mn)
8.4.1. U.K.
8.4.2. Germany
8.4.3. Rest of Europe

Chapter 9. Asia Pacific PDND Market Analysis, 2019 – 2029
9.1. Asia Pacific PDND Market, by Drug Type, 2019 – 2029 (US$ Mn)
9.2. Asia Pacific PDND Market, by DiseaseType, 2019 – 2029 (US$ Mn)
9.3. Asia Pacific PDND Market, by Application area, 2019 – 2029 (US$ Mn)
9.4. Asia Pacific PDND Market, by Country/Region, 2019 – 2029 (US$ Mn)
9.4.1. Japan
9.4.2. China
9.4.3. Rest of APAC

Chapter 10. Latin America PDND Market Analysis, 2019 – 2029
10.1. Latin America PDND Market, by Drug Type, 2019 – 2029 (US$ Mn)
10.2. Latin America PDND Market, by DiseaseType, 2019 – 2029 (US$ Mn)
10.3. Latin America PDND Market, by Application area, 2019 – 2029 (US$ Mn)
10.4. Latin America PDND Market, by Country/Region, 2019 – 2029 (US$ Mn)
10.4.1. Brazil
10.4.2. Mexico
10.4.3. Rest of Latin America

Chapter 11. Middle East & Africa (MEA) PDND Market Analysis, 2019 – 2029
11.1. Middle East & Africa (MEA) PDND Market, by Drug Type, 2019 – 2029 (US$ Mn)
11.2. Middle East & Africa (MEA) PDND Market, by Disease Type, 2019 – 2029 (US$ Mn)
11.3. Middle East & Africa (MEA) PDND Market, by Application area, 2019 – 2029 (US$ Mn)
11.4. MEA PDND Market, by Region, 2019 – 2029 (US$ Mn)
11.4.1. GCC
11.4.2. Rest of MEA

Chapter 12. Company Profiles
12.1. Daiichi Sankyo Company, Limited
12.1.1. Business Description
12.1.2. Financial Information (Subject to data availability)
12.1.3. Product Portfolio
12.1.4. Key Developments
12.2. Eli Lilly and Company
12.3. Johnson & Johnson Services, Inc
12.4. Novartis AG
12.5. Pfizer Inc.
12.6. Grunenthal GmbH
12.7 ViroMed Co.
12.8 Collegium Pharmaceutical, Inc
12.9 Acorda Therapeutics, Inc
12.10 Zydus Pharmaceuticals
12.11 Mallinckrodt, Inc
12.12 Macleods Pharmaceuticals Ltd.
12.13 Lupin Pharmaceuticals
PDND - Painful Diabetic Neuropathy Drugs
Note: Product cover images may vary from those shown
  • Daiichi Sankyo Company
  • Eli Lilly and Company
  • Johnson & Johnson Services
  • Novartis AG
  • Pfizer Inc
  • Grunenthal GmbH
  • ViroMed Co
  • Collegium Pharmaceutical
  • Acorda Therapeutics
  • Zydus Pharmaceuticals
  • Mallinckrodt
  • Macleods Pharmaceuticals Ltd
  • Lupin Pharmaceuticals.
Note: Product cover images may vary from those shown
Adroll
adroll